Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline 83% of subjects ...
The last time I spoke about Madrigal Pharmaceuticals (MDGL), it was with respect to a Seeking Alpha article entitled "Madrigal Pharmaceuticals: Rezdiffra Expansion Avenues Shift Focus To Long Term." ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results